Literature DB >> 8645630

Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells.

M Borrás1, I Laios, A el Khissiin, H S Seo, F Lempereur, N Legros, G Leclercq.   

Abstract

Effect of estrogens and antiestrogens (AEs) on estrogen receptor (ER) half-life was analyzed in MCF-7 cells by assessing its progressive disappearance after covalent labeling in situ with [3H]tamoxifen aziridine ([3H]TAZ). Cells were incubated for 1 h with 20 nM [3H]TAZ either in the absence or presence of a 500-fold excess of unlabeled estradiol (E2) (non-specific binding). The entire ER population was labeled by this method as established by subsequent incubation of the cells with [125I]E2. [3H]TAZ labeled cells were maintained in culture for additional 5 h in the absence (control) or presence of increasing amounts (0.1 nM - 1 microM) of either a given estrogen (E2, estrone, diethylstilbestrol, bisphenol), a pure AE (RU 58 668, ICI 164 384) or an AE with residual estrogenic activity (RU 39 411, 4-hydroxytamoxifen, keoxifene). The progressive disappearance of nuclear and cytosolic [3H]TAZ-ER complex during 5 h incubation were assessed by their immunoprecipitation with anti-ER monoclonal antibody (H 222) followed by scintillation counting or SDS-PAGE and fluorography. Fading of labeled receptors was extremely slow (approximately 10% loss after 6 h) in absence of any hormone/antihormone indicating a long half-life of the [3H]TAZ-ER complex. Addition of estrogens as well as pure AEs led to a dramatic reduction of the half-life while AEs with residual estrogenic activity were extremely less efficient in this regard providing an explanation for the ability of latter compounds to up-regulate the receptor since they do not affect ER mRNA synthesis and stability. Receptor disappearance induced by estrogens was closely related to their binding affinity for ER. Newly synthesized ER emerged during the treatment with hormones or antihormones seems to be implicated in the phenomenon since [3H]TAZ was covalently bound and could, therefore, not be displaced by these compounds. Induction of synthesis of a short half-life peptide(s) with degradative activity was demonstrated by addition of cycloheximide or puromycine (both at 50 microM) which completely blocked ER disappearance. The fact that no cleavage products of ER were detected by SDS-PAGE suggested a lysosomial hydrolysis. Hence, hormonal modulation of only a part of ERs may down-regulate their total population until it reaches the steady-state level.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8645630     DOI: 10.1016/0960-0760(95)00272-3

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  13 in total

1.  Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1.

Authors:  Prashant Rajbhandari; Greg Finn; Natalia M Solodin; Kiran K Singarapu; Sarata C Sahu; John L Markley; Kelley J Kadunc; Stephanie J Ellison-Zelski; Anastasia Kariagina; Sandra Z Haslam; Kun Ping Lu; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

2.  Defining estrogenic mechanisms of bisphenol A analogs through high throughput microscopy-based contextual assays.

Authors:  Fabio Stossi; Michael J Bolt; Felicity J Ashcroft; Jane E Lamerdin; Jonathan S Melnick; Reid T Powell; Radhika D Dandekar; Maureen G Mancini; Cheryl L Walker; John K Westwick; Michael A Mancini
Journal:  Chem Biol       Date:  2014-05-22

3.  Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.

Authors:  A Rodriguez-Gonzalez; K Cyrus; M Salcius; K Kim; C M Crews; R J Deshaies; K M Sakamoto
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

4.  Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer.

Authors:  Ifeyinwa Obiorah; Surojeet Sengupta; Ramona Curpan; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2014-03-07       Impact factor: 4.436

Review 5.  Fulvestrant and the sequential endocrine cascade for advanced breast cancer.

Authors:  S Johnston
Journal:  Br J Cancer       Date:  2004-03       Impact factor: 7.640

6.  Activation of the human estrogen receptor by the antiestrogens ICI 182,780 and tamoxifen in yeast genetic systems: implications for their mechanism of action.

Authors:  M W Dudley; C Q Sheeler; H Wang; S Khan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

7.  The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.

Authors:  Zhinong Jiang; Junlan Guo; Jianguo Shen; Mei Jin; Shuduo Xie; Linbo Wang
Journal:  J Exp Clin Cancer Res       Date:  2012-05-03

8.  Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection.

Authors:  Carmen Criscitiello; Debora Fumagalli; Kamal S Saini; Sherene Loi
Journal:  Onco Targets Ther       Date:  2010-12-17       Impact factor: 4.147

9.  Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals.

Authors:  H R Andersen; A M Andersson; S F Arnold; H Autrup; M Barfoed; N A Beresford; P Bjerregaard; L B Christiansen; B Gissel; R Hummel; E B Jørgensen; B Korsgaard; R Le Guevel; H Leffers; J McLachlan; A Møller; J B Nielsen; N Olea; A Oles-Karasko; F Pakdel; K L Pedersen; P Perez; N E Skakkeboek; C Sonnenschein; A M Soto
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

10.  The antiestrogen ICI 182,780 decreases the expression of estrogen receptor-alpha but has no effect on estrogen receptor-beta and androgen receptor in rat efferent ductules.

Authors:  Cleida A Oliveira; Rong Nie; Kay Carnes; Luiz R Franca; Gail S Prins; Philippa T K Saunders; Rex A Hess
Journal:  Reprod Biol Endocrinol       Date:  2003-10-10       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.